Navigation Links
Neurologix Announces Second Quarter 2011 Financial Results
Date:8/11/2011

lating to the Company are based upon the beliefs of management and assumptions made by and information currently available to the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, or performance, as well as underlying assumptions and statements that are other than statements of historical fact. When used in this document, the words "expects," "promises," "anticipates," "estimates," "plans," "intends," "projects," "predicts," "believes," "may" or "should," and similar expressions, are intended to identify forward-looking statements. These statements reflect the current view of the Company's management with respect to future events. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the following:

  • The Company is still in the development stage and has not generated any revenues. From inception through June 30, 2011, it incurred net losses and negative cash flows from operating activities of approximately $63.0 million and $48.9 million, respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseeable future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.
  • At June 30, 2011, the Company had cash and cash equivalents of approximately $3.5 million. Based on its cash flow projections, the Company will need additional financing to carry out its planned business activities and plan o
    '/>"/>

  • SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
    2. Bion Announces New U.S. Patent for Phosphorus Removal
    3. ViaCyte Announces Executive Management Changes
    4. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
    5. Dendreon Announces Webcast Presentation at Canaccord Genuity Growth Conference
    6. Osteologix Announces Completion of Corporate Consolidation
    7. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results
    8. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
    9. Rigel Announces Second Quarter 2011 Financial Results
    10. WAVi Co. Announces Collaborative Agreement with SomaLogic, Inc.
    11. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... and NEW YORK , Dec. ... biopharmaceutical company advancing patient care in critical areas, announced the ... common stock, and warrants to purchase up to an aggregate ... $4.00 per share and $.01 per warrant.  The warrants have ...
    (Date:12/24/2014)... BioLife Solutions , Inc. (NASDAQ: BLFS ), a ... hypothermic storage and cryopreservation freeze media and ... ("BioLife" or the "Company"), today announced that it will hold ... (the "Annual Meeting"). Because the expected date for ...
    (Date:12/24/2014)... 2014 GMO corn cases filed across the ... the process of being consolidated in a Kansas federal court ... AG MIR 162 Corn Litigation, MDL No. 2591 in the ... of the Syngenta GMO corn multidistrict litigation (MDL) has been ...
    (Date:12/24/2014)... 23, 2014 SoundConnect’s ... introduce cutting edge communication technology, provide continued education ... This webinar series demonstrates online communication features and ... web conferencing’s most innovative and powerful tools. , ...
    Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
    ... March 23 Nereus Pharmaceuticals, Inc., a pioneer ... announced that it is conducting a randomized Phase ... (VDA) NPI-2358 in combination with standard chemotherapy (docetaxel) ... This study follows on positive outcomes in ...
    ... Corporation (Nasdaq: PRXL ), a leading ... Company has received the Best Performing Clinical Research ... for life sciences businesses encouraged by the Economic ... to PAREXEL at the BioSingapore Asia/Pacific Biotechnology Awards ...
    ... York, December 1, 2008 Although naturally occurring smallpox ... might obtain smallpox from a laboratory and release it ... smallpox vaccine may be insufficient for universal administration. In ... The American Journal of Medicine , researchers found ...
    Cached Biology Technology:Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer 2Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer 3PAREXEL Receives BioSingapore Award for Best Performing CRO 2PAREXEL Receives BioSingapore Award for Best Performing CRO 3PAREXEL Receives BioSingapore Award for Best Performing CRO 4New study indicates smallpox vaccination effective for decades 2
    (Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM announced ... audit to confirm its adherence to current U.S. Food ... to conduct regulated smart device and smart phone application ... research quality. "HITLAB is determined to improve ...
    (Date:12/15/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Recognition Market 2015-2019" report to their offering. ... recognition is a technology used for the identification of ... of a person such as nose, jaw edges, mouth, ...
    (Date:12/11/2014)... 2014  Data Sciences International (DSI), the global leader ... series of digital telemetry implants to meet the ... part of the PhysioTel™ Digital platform, was designed ... data when incorporating functional endpoints into repeat-dose toxicology ...
    Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
    ... Wiley & Sons, Inc., today announced the launch ... Energy and Environment , publishing online this month. ... collaboration between different disciplines of science and technology, ... scientists, economists, sociologists and policy-makers. ...
    ... and BGI have announced a major joint initiative ... new venture will provide a world-class research and ... approaches in molecular biology, including DNA sequencing, metabolomics ... to environmental change through to disease susceptibility and ...
    ... for some time that throwing off the body,s circadian ... whose sleep-wake cycles are disrupted by night shifts are ... obesity and cancer. Researchers at the Salk Institute ... link between circadian rhythm disturbances and an increased inflammatory ...
    Cached Biology News:Wiley launches new interdisciplinary review WIREs Energy and Environment 2BGI partners with the University of Birmingham 2BGI partners with the University of Birmingham 3Scientists discover molecular link between circadian clock disturbances and inflammatory diseases 2Scientists discover molecular link between circadian clock disturbances and inflammatory diseases 3
    ...
    Rb anti-Occludin (C-term GST)...
    Rabbit polyclonal to EDG2 ( Abpromise for all tested applications). entrezGeneID: 1902 SwissProtID: Q92633...
    ... ZMD.330. Immunogen: Synthetic peptide derived from ... and mouse protein kinase C zeta isoform ... and mouse PKCzeta protein. Recognizes PKCzeta ... cross-react with PKCiota/lambda. Reactivity: Mouse Rat ...
    Biology Products: